Massive fetomaternal hemorrhage and successful prevention of maternal RhD alloimmunization: A case report.

IF 2 3区 医学 Q2 HEMATOLOGY
Transfusion Pub Date : 2026-10-01 Epub Date: 2026-08-19 DOI:10.1111/trf.70318
Sajjad Hassan, Angela Essa, Lauren Orr, Corina N Schoen, Chester Andrzejewski
{"title":"Massive fetomaternal hemorrhage and successful prevention of maternal RhD alloimmunization: A case report.","authors":"Sajjad Hassan, Angela Essa, Lauren Orr, Corina N Schoen, Chester Andrzejewski","doi":"10.1111/trf.70318","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Massive fetomaternal hemorrhage can lead to significant fetal morbidity or mortality. RhD negative patients require appropriate treatment to prevent alloimmunization in subsequent pregnancies. Few cases with follow-up into future pregnancies have been reported.</p><p><strong>Case report and results: </strong>30-year-old gravida 3 para 1 presented at 40 weeks and 2 days gestation for late term evaluation. Ultrasonography identified an intrauterine fetal demise. The patient was O RhD negative and had previously received Rh immunoglobin (RhIG) at 26 weeks of gestation. The patient was induced and delivered a 3,450 gram stillborn fetus. Kleihauer-Betke testing performed and revealed massive fetomaternal hemorrhage with a result of 5.4-6.0%. The calculated fetomaternal hemorrhage was estimated to be 281.6 mL (approaching the total estimated fetal blood volume of 293 mL). The patient received 3 vials of intramuscular RhIG (300 μg/vial), 2 vials of intravenous RhIG (1,000 μg/vial), and 1 vial of intravenous RhIG (300 μg/vial) for a total RhIG dose of 3,200 μg, over a 3-day period, with no adverse clinical sequelae. Serological investigations for anti-D antibodies remained positive until 6 months and were inconclusive at 8 months postpartum. At 10 months postpartum, she was 9 weeks pregnant and no anti-D antibodies were detected. With this subsequent pregnancy, she was treated with routine RhIG and delivered a healthy RhD positive neonate.</p><p><strong>Conclusion: </strong>Adequate dosing of RhIG can be achieved to prevent alloimmunization, even in massive fetomaternal hemorrhages. After large doses of RhIG, anti-D antibodies may persist for several months and do not necessarily indicate maternal alloimmunization.</p>","PeriodicalId":23266,"journal":{"name":"Transfusion","volume":" ","pages":"2017-2024"},"PeriodicalIF":2.0000,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13674137/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Transfusion","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/trf.70318","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/8/19 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Massive fetomaternal hemorrhage can lead to significant fetal morbidity or mortality. RhD negative patients require appropriate treatment to prevent alloimmunization in subsequent pregnancies. Few cases with follow-up into future pregnancies have been reported.

Case report and results: 30-year-old gravida 3 para 1 presented at 40 weeks and 2 days gestation for late term evaluation. Ultrasonography identified an intrauterine fetal demise. The patient was O RhD negative and had previously received Rh immunoglobin (RhIG) at 26 weeks of gestation. The patient was induced and delivered a 3,450 gram stillborn fetus. Kleihauer-Betke testing performed and revealed massive fetomaternal hemorrhage with a result of 5.4-6.0%. The calculated fetomaternal hemorrhage was estimated to be 281.6 mL (approaching the total estimated fetal blood volume of 293 mL). The patient received 3 vials of intramuscular RhIG (300 μg/vial), 2 vials of intravenous RhIG (1,000 μg/vial), and 1 vial of intravenous RhIG (300 μg/vial) for a total RhIG dose of 3,200 μg, over a 3-day period, with no adverse clinical sequelae. Serological investigations for anti-D antibodies remained positive until 6 months and were inconclusive at 8 months postpartum. At 10 months postpartum, she was 9 weeks pregnant and no anti-D antibodies were detected. With this subsequent pregnancy, she was treated with routine RhIG and delivered a healthy RhD positive neonate.

Conclusion: Adequate dosing of RhIG can be achieved to prevent alloimmunization, even in massive fetomaternal hemorrhages. After large doses of RhIG, anti-D antibodies may persist for several months and do not necessarily indicate maternal alloimmunization.

母婴大出血与母体RhD同种异体免疫成功预防1例报告。
背景:大量的胎儿出血可导致严重的胎儿发病率或死亡率。RhD阴性患者需要适当的治疗,以防止在随后的怀孕同种异体免疫。对未来妊娠进行随访的病例很少。病例报告和结果:30岁孕妇第3段,孕40周2天,进行晚期评估。超声检查发现宫内胎儿死亡。患者为O Rh阴性,妊娠26周时接受过Rh免疫球蛋白(rhg)治疗。病人被引产并产下了一个3450克的死胎。Kleihauer-Betke检查显示大量胎母出血,结果为5.4% -6.0%。计算出的胎儿出血估计为281.6 mL(接近估计的胎儿总血容量293 mL)。患者肌注RhIG 3瓶(300 μg/瓶)、静脉注射RhIG 2瓶(1000 μg/瓶)、静脉注射RhIG 1瓶(300 μg/瓶),RhIG总剂量为3200 μg,疗程3 d,无不良临床后遗症。抗d抗体的血清学检查直到产后6个月仍呈阳性,产后8个月尚无定论。产后10个月,怀孕9周,未检出抗d抗体。在随后的怀孕中,她接受了常规RhIG治疗,并生下了一个健康的RhD阳性新生儿。结论:适当剂量的RhIG可以预防同种异体免疫,即使在大出血的胎母中也是如此。大剂量RhIG后,抗d抗体可能持续数月,不一定表明母体同种异体免疫。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Transfusion
Transfusion 医学-血液学
CiteScore
4.70
自引率
20.70%
发文量
426
审稿时长
1 months
期刊介绍: TRANSFUSION is the foremost publication in the world for new information regarding transfusion medicine. Written by and for members of AABB and other health-care workers, TRANSFUSION reports on the latest technical advances, discusses opposing viewpoints regarding controversial issues, and presents key conference proceedings. In addition to blood banking and transfusion medicine topics, TRANSFUSION presents submissions concerning patient blood management, tissue transplantation and hematopoietic, cellular, and gene therapies.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书